N-BUTYLDEOXYNOJIRIMYCIN
- CAS No.
- 72599-27-0
- Chemical Name:
- N-BUTYLDEOXYNOJIRIMYCIN
- Synonyms
- nb-dnj;Zavesca;OGT 918;megasat;SC-48334;Mg gross;miglusta;N-Butylmoranoline;N-BUTYLDEOXYNOJIRIMYCIN;N-BUTYL-1-DEOXYNOJIRIMYCIN
- CBNumber:
- CB0125257
- Molecular Formula:
- C10H21NO4
- Molecular Weight:
- 219.28
- MOL File:
- 72599-27-0.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/8/7 19:09:28
| Melting point | 126-127℃ |
|---|---|
| alpha | D25 -15.9° (c = 0.77 in water) |
| Boiling point | 394.7±42.0 °C(Predicted) |
| Density | 1.234 |
| RTECS | TN4350150 |
| storage temp. | 2-8°C |
| solubility | DMSO 44 mg/mL (200.66 mM) Ethanol 22 mg/mL (100.33 mM) Water 44 mg/mL (200.66 mM) |
| form | Powder |
| pka | 13.72±0.70(Predicted) |
| color | White |
| Water Solubility | Soluble in water at 10mg/ml |
| InChI | InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1 |
| InChIKey | UQRORFVVSGFNRO-UTINFBMNSA-N |
| SMILES | N1(CCCC)C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H315-H319 |
| Precautionary statements | P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313 |
| WGK Germany | 3 |
| HS Code | 2933399990 |
N-BUTYLDEOXYNOJIRIMYCIN price More Price(2)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | B8299 | N-Butyldeoxynojirimycin film (dried in situ) | 72599-27-0 | 1MG | ₹35354.45 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | B8299 | N-Butyldeoxynojirimycin film (dried in situ) | 72599-27-0 | 5MG | ₹139642.5 | 2022-06-14 | Buy |
N-BUTYLDEOXYNOJIRIMYCIN Chemical Properties,Uses,Production
Description
Miglustat is an N-alkylated iminosugar, launched as an oral treatment for mild to moderate type 1 Gaucher’s disease in adult patients for whom enzyme replacement therapy is not a therapeutic option. It is readily synthesized from D-glucose in three steps by first converting to N-butylglucamine via reductive amination with butylamine, followed by a microbial oxidation to an aminofuranose intermediate and subsequent reductive cyclization. Type 1 Gaucher’s disease is a metabolic disorder caused by the lysosomal accumulation of certain glycosphingolipids (GSLs) as a result of deficiency in their degradation. Enlargement of the liver and spleen, low blood platelet and bone lesions are among the key symptoms of this disease. Miglustat acts by inhibiting glucosylceramide synthase, a glucosyl transferase enzyme in the biosynthesis of most GSLs, which results in the lowering of GSLs to a level that can be effectively cleared. Up to 50% reduction in liver and splenocyte GSL levels are achieved in mice by long-term administration of Miglustat (600– 1800 mg/kg/day for 118 days). Miglustat, dosed at 50 and 100 mg in Gaucher patients, exhibits dose proportionate pharmacokinetics (tmax=2.5 h, t1/2=6 to 7 h) and ＞90% oral bioavailability. Steady-state plasma levels are reached after 4–6 weeks of treatment. Miglustat is not significantly metabolized in humans and the major route of excretion is renal. In clinical trials, efficacy was demonstrated by significant reductions in liver and spleen volumes (12 and 19%, respectively) at 12 months and increase in hemoglobin and platelet count (0.91 g/dL and 13.6×109/l, respectively) at 24 months. Miglustat is generally well tolerated by patients and the most common side effects are diarrhea and weight loss.
Uses
Treatment of glycolipid storage diseases.
Definition
ChEBI: A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.
General Description
N-Butyldeoxynojirimycin is an alkylated product of imino sugar deoxynojirimycin.
Biological Activity
Orally active α -glucosidase I and II and ceramide-specific glycosyltransferase inhibitor. Rescues trafficking-deficient F508del-CTFR in human airway epithelial cells via inhibition of ER α -glucosidases I and II. Also has broad spectrum antiviral activity.
N-BUTYLDEOXYNOJIRIMYCIN Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Varanous Labs Pvt Ltd | +91-7036248882 +91-7036248882 | Hyderabad, India | 1541 | 58 | Inquiry |
| Mylan Laboratories Ltd | +91-4023550543 +91-4030866666 | Telangana, India | 150 | 58 | Inquiry |
| Apicore Pharmaceuticals Pvt Ltd | +91-2662267177 +91-2662267166 | Gujarat, India | 181 | 58 | Inquiry |
| Apothecon Pharmaceuticals Pvt Ltd | +91-2662244212 +91-9099007601 | Gujarat, India | 28 | 58 | Inquiry |
| Rivashaa Agrotech Biopharma Pvt. Ltd. | +91-26463395 +91-7926462688 | Gujarat, India | 1615 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| Chengdu Biopurify Phytochemicals Ltd. | +8618080483897 | China | 3777 | 58 | Inquiry |
| Hebei Mojin Biotechnology Co., Ltd | +8613288715578 | China | 12455 | 58 | Inquiry |
| Hebei Ganmiao New material Technology Co., LTD | +86-17332992504 +86-17332992504 | China | 300 | 58 | Inquiry |
72599-27-0(N-BUTYLDEOXYNOJIRIMYCIN)Related Search:
1of4
chevron_right